Skip to Content

Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Download PQI pdf 0.22MB

Last Updated: September 27, 2023

By: Jeff Engle, PharmD, MS

About this PQI

The purpose of this PQI is to discuss the clinical considerations of tafasitamab-cxix (Monjuvi®) to optimize the outcomes for patients with relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI